Exiris
Pre-clinicalExiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies: Cancer stem cell platform, Drug conjugate technology and Antibody ID technology.
Founded
2015
Focus
AntibodiesBiologics
About
Exiris makes use of several platform technologies for target identification and validation. In addition, Exiris is developing its own antibody and drug conjugate technologies: Cancer stem cell platform, Drug conjugate technology and Antibody ID technology.
Funding History
2Total raised: $18.2M
Series A$15MSofinnova PartnersNov 15, 2023
Seed$3.2MPanakès PartnersMar 15, 2022
Company Info
TypePrivate
Founded2015
LocationMilan, Italy
StagePre-clinical
Contact
SIMILAR COMPANIES
AAVantgarde Bio
Pre-clinical · Milan
AB ANALITICA
Pre-clinical · Padua
BetaGlue Therapeutics
Phase 1 · Milan
Adienne Pharma and Biotech
Pre-clinical · Milan
Advaxia Biologics
Pre-clinical · Milan
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile